|
1
|
Ikeguchi M, Miyake T, Matsunaga T,
Yamamoto M, Fukumoto Y, Yamada Y, Fukuda K, Saito H, Tatebe S and
Tsujitani S: Recent results of therapy for scirrhous gastric
cancer. Surg Today. 39:290–294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hippo Y, Yashiro M, Ishii M, Taniguchi H,
Tsutsumi S, Hirakawa K, Kodama T and Aburatani H: Differential gene
expression profiles of scirrhous gastric cancer cells with high
metastatic potential to peritoneum or lymph nodes. Cancer Res.
61:889–895. 2001.PubMed/NCBI
|
|
3
|
Kitamura K, Beppu R, Anai H, Ikejiri K,
Yakabe S, Sugimachi K and Saku M: Clinicopathologic study of
patients with Borrmann type IV gastric carcinoma. J Surg Oncol.
58:112–117. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakamura R, Saikawa Y, Wada N, Yoshida M,
Kubota T, Kumai K and Kitajima M: Retrospective analysis of
prognosis for scirrhous-type gastric cancer: One institution's
experience. Int J Clin Oncol. 12:291–294. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohtsu A, Boku N, Yoshida S, Miyata Y,
Shirao K, Shimada Y and Kurihara M: Japan Clinical Oncology Group:
Response of the primary lesion in gastric cancer to
chemotherapeutic trials. Int J Clin Onco1. 3:3–6. 1998. View Article : Google Scholar
|
|
6
|
Koizumi W, Narahara H, Hara T, Takagane A,
Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama
W, et al: S-1 plus cisplatin versus S-1 alone for first-line
treatment of advanced gastric cancer (SPIRITS trial): A phase III
trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: RAINBOW Study Group: Ramucirumab plus paclitaxel versus placebo
plus paclitaxel in patients with previously treated advanced
gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fuchs CS, Tomasek J, Yong CJ, Dumitru F,
Passalacqua R, Goswami C, Safran H, dos Santos LV, Aprile G, Ferry
DR, et al: REGARD Trial Investigators: Ramucirumab monotherapy for
previously treated advanced gastric or gastro-oesophageal junction
adenocarcinoma (REGARD): An international, randomised, multicentre,
placebo-controlled, phase 3 trial. Lancet. 383:31–39. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nashimoto A, Akazawa K, Isobe Y, Miyashiro
I, Katai H, Kodera Y, Tsujitani S, Seto Y, Furukawa H, Oda I, et
al: Gastric cancer treated in 2002 in Japan: 2009 annual report of
the JGCA nationwide registry. Gastric Cancer. 16:1–27. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yanagihara K, Seyama T, Tsumuraya M,
Kamada N and Yokoro K: Establishment and characterization of human
signet ring cell gastric carcinoma cell lines with amplification of
the c-myc oncogene. Cancer Res. 51:381–386. 1991.PubMed/NCBI
|
|
11
|
Semba S, Kodama Y, Ohnuma K, Mizuuchi E,
Masuda R, Yashiro M, Hirakawa K and Yokozaki H: Direct
cancer-stromal interaction increases fibroblast proliferation and
enhances invasive properties of scirrhous-type gastric carcinoma
cells. Br J Cancer. 101:1365–1373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ishida M, Gomyo Y, Ohfuji S, Ikeda M,
Kawasaki H and Ito H: Evidence that expression of a mutated p53
gene attenuates apoptotic cell death in human gastric
intestinal-type carcinomas in vivo. Jpn J Cancer Res. 88:468–475.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boku N, Yamamoto S, Shirao K, Doi T,
Sawaki A, Koizumi W, Saito H, Yamaguchi K, Kimura A, et al:
Randomized phase III study of 5-fluorouracil (5-FU) alone versus
combination of irinotecan and cisplatin (CP) versus S-1 alone in
advanced gastric cancer (JCOG9912). J Clin Oncol 2007 ASCO Annual
Meeting Proceedings. 25:LBA45132007.
|
|
14
|
Ichikawa W and Sasaki Y: Challenges in
predicting the clinical outcome in S-1-based chemotherapy for
gastric cancer patients. Int J Clin Oncol. 13:206–211. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shitara K, Ishiguro A, Munakata M, Wada R
and Sakata Y: Retrospective analysis of stage IV advanced gastric
cancer treated with S-1 or other chemotherapy. Int J Clin Oncol.
11:367–374. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sato K, Akaike T, Kojima Y, Ando M, Nagao
M and Maeda H: Evidence of direct generation of oxygen free
radicals from heterocyclic amines by NADPH/cytochrome P-450
reductase in vitro. Jpn J Cancer Res. 83:1204–1209. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lanks KW, Gao JP and Sharma T:
Photodynamic enhancement of doxorubicin cytotoxicity. Cancer
Chemother Pharmacol. 35:17–20. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawakami T, Kawamura K, Fujimori K, Koike
A and Amano F: Influence of the culture medium on the production of
nitric oxide and expression of inducible nitric oxide synthase by
activated macrophages in vitro. Biochem Biophys Rep. 5:328–334.
2016.
|
|
19
|
Leist M, Single B, Castoldi AF, Kühnle S
and Nicotera P: Intracellular adenosine triphosphate (ATP)
concentration: A switch in the decision between apoptosis and
necrosis. J Exp Med. 185:1481–1486. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kinoshita T, Konishi M, Nakagohri T, Inoue
K, Oda T, Takahashi S, Boku N, Ohtsu A and Yoshida S: Neoadjuvant
chemotherapy with S-1 for scirrhous gastric cancer: A pilot study.
Gastric Cancer. 6:(Suppl 1). S40–S44. 2003. View Article : Google Scholar
|
|
22
|
Ohtsu A: Current status and future
prospects of chemotherapy for metastatic gastric cancer: A review.
Gastric Cancer. 8:95–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Johnstone RW, Ruefli AA and Lowe SW:
Apoptosis: A link between cancer genetics and chemotherapy. Cell.
108:153–164. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Johnston PG, Lenz HJ, Leichman CG,
Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate
synthase gene and protein expression correlate and are associated
with response to 5-fluorouracil in human colorectal and gastric
tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
|
|
25
|
Yu R, Shtil AA, Tan TH, Roninson IB and
Kong AN: Adriamycin activates c-jun N-terminal kinase in
human leukemia cells: A relevance to apoptosis. Cancer Lett.
107:73–81. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Henkels KM and Turchi JJ:
Cisplatin-induced apoptosis proceeds by caspase-3-dependent and
-independent pathways in cisplatin-resistant and -sensitive human
ovarian cancer cell lines. Cancer Res. 59:3077–3083.
1999.PubMed/NCBI
|
|
27
|
Marcelli M, Cunningham GR, Walkup M, He Z,
Sturgis L, Kagan C, Mannucci R, Nicoletti I, Teng B and Denner L:
Signaling pathway activated during apoptosis of the prostate cancer
cell line LNCaP: Overexpression of caspase-7 as a new gene therapy
strategy for prostate cancer. Cancer Res. 59:382–390.
1999.PubMed/NCBI
|
|
28
|
Matsura T, Kai M, Fujii Y, Ito H and
Yamada K: Hydrogen peroxide-induced apoptosis in HL-60 cells
requires caspase-3 activation. Free Radic Res. 30:73–83. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ueta E, Yoneda K, Yamamoto T and Osaki T:
Manganese superoxide dismutase negatively regulates the induction
of apoptosis by 5-fluorouracil, peplomycin and gamma-rays in
squamous cell carcinoma cells. Jpn J Cancer Res. 90:555–564. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alexandre J, Nicco C, Chéreau C, Laurent
A, Weill B, Goldwasser F and Batteux F: Improvement of the
therapeutic index of anticancer drugs by the superoxide dismutase
mimic mangafodipir. J Natl Cancer Inst. 98:236–244. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yanagihara K and Tsumuraya M: Transforming
growth factor β1 induces apoptotic cell death in
cultured human gastric carcinoma cells. Cancer Res. 52:4042–4045.
1992.PubMed/NCBI
|
|
32
|
Ohta S, Yanagihara K and Nagata K:
Mechanism of apoptotic cell death of human gastric carcinoma cells
mediated by transforming growth factor β. Biochem J. 324:777–782.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Romano G, Santi L, Bianco MR, Giuffrè MR,
Pettinato M, Bugarin C, Garanzini C, Savarese L, Leoni S, Cerrito
MG, et al: The TGF-β pathway is activated by 5-fluorouracil
treatment in drug resistant colorectal carcinoma cells. Oncotarget.
7:22077–22091. 2016.PubMed/NCBI
|
|
34
|
Liu RM and Desai LP: Reciprocal regulation
of TGF-β and reactive oxygen species: A perverse cycle for
fibrosis. Redox Biol. 6:565–577. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pan X, Zhang X, Sun H, Zhang J, Yan M and
Zhang H: Autophagy inhibition promotes 5-fluorouraci-induced
apoptosis by stimulating ROS formation in human non-small cell lung
cancer A549 cells. PLoS One. 8:e566792013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rosenberg B: Fundamental studies with
cisplatin. Cancer. 55:2303–l6. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hecquet B, Vennin P, Fournier C, Lefebvre
JL, Caty A, Bonneterre J, Adenis L and Demaille A: Platinum
concentration in human tumors of head and neck, uterine cervix, and
breast following treatment with cisplatin. Cancer Chemother
Pharmacol. 15:310–312. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ohtsu A, Shimada Y, Shirao K, Boku N,
Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, et
al: Japan Clinical Oncology Group Study (JCOG9205): Randomized
phase III trial of fluorouracil alone versus fluorouracil plus
cisplatin versus uracil and tegafur plus mitomycin in patients with
unresectable, advanced gastric cancer: The Japan Clinical Oncology
Group Study (JCOG9205). J Clin Oncol. 21:54–59. 2003. View Article : Google Scholar : PubMed/NCBI
|
